U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C32H55N4O
Molecular Weight 511.8053
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of THONZONIUM

SMILES

CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(OC)C=C1)C2=NC=CC=N2

InChI

InChIKey=IOYZYMQFUSNATM-UHFFFAOYSA-N
InChI=1S/C32H55N4O/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-27-36(2,3)28-26-35(32-33-24-19-25-34-32)29-30-20-22-31(37-4)23-21-30/h19-25H,5-18,26-29H2,1-4H3/q+1

HIDE SMILES / InChI
Thonzonium Bromide is a cationic surface-active compound. As an additive to pharmacologic formulations, thonzonium bromide causes dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. Thonzonium bromide is a component of FDA-approved Coly-Mycin S Otic, used for treating infections of the ear caused by certain bacteria. It has being shown that Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo, suggesting that Thonzonium bromide might be a useful alternative therapy in preventing or treating osteolytic diseases..

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
COLY-MYCIN S

Approved Use

Cortisporin®-TC Otic Suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics.

Launch Date

1962
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Mice: 5 mg/kg body weight, subcutaneous injection
Route of Administration: Other
Mature osteoclasts (OCs) exposed to Thonzonium (100 or 200 nM) for 48 h demonstrated attenuated capacity to resorb bone (reduction of 30% and 80% respectively).
Name Type Language
THONZONIUM
Common Name English
Tonzonium [WHO-DD]
Common Name English
N-(2-((4-METHOXYBENZYL)(PYRIMIDIN-2-YL)AMINO)ETHYL)-N,N-DIMETHYLHEXADECAN-1-AMINIUM
Systematic Name English
TONZONIUM
WHO-DD  
Common Name English
THONZONIUM ION
Common Name English
THONZONIUM CATION
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID8048232
Created by admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
PRIMARY
DAILYMED
Z05ZE98FV8
Created by admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
PRIMARY
RXCUI
237058
Created by admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
PRIMARY RxNorm
PUBCHEM
5456
Created by admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
PRIMARY
DRUG BANK
DB09552
Created by admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
PRIMARY
DRUG CENTRAL
4605
Created by admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
PRIMARY
CAS
25466-36-8
Created by admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
PRIMARY
FDA UNII
Z05ZE98FV8
Created by admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
PRIMARY
WIKIPEDIA
Thonzonium
Created by admin on Fri Dec 15 15:47:42 GMT 2023 , Edited by admin on Fri Dec 15 15:47:42 GMT 2023
PRIMARY